2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - R02-R05
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

884 The IGF2BP3-CBFA2T3 axis links oncogenic KRAS to oxidative phosphorylation in JMML hematopoietic stem and progenitor cells

Jingliao Zhang, MD, Anni Lu2, Yangping Wu, PhD3, Yongjuan Duan4, Nuo Li5, Danjing Wang6, Linlin Jin7, Ziqi Hu8, Yan Zhu9, Ye Guo10, Li Zhang11, Yumei Chen12, Xiaojuan Chen13, Yao Zou14, Tianyuan Hu15, Xiaofan Zhu, MD16, Peng Wu, PhD17, Wenyu Yang18, Yingchi Zhang19
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
9 State Key Laboratory of Digital Medical Engineering, Key Laboratory of Biomedical Engineering of Hainan Province, School of Biomedical Engineering, Hainan University, Hainan, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
16 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
17 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
18 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
19 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China

Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric myeloproliferative neoplasm driven predominantly by aberrant RAS signaling, yet the molecular mechanisms that sustain leukemia-propagating hematopoietic stem and progenitor cells (HSPCs) remain poorly defined. To identify targetable programs downstream of oncogenic KRAS, we integrated single-cell transcriptomic and chromatin accessibility analyses of primary KRAS-mutant JMML samples with genetic and functional studies in vitro and in vivo. Single-cell transcriptomic analysis demonstrated marked expansion of HSC/MPP populations in KRAS-mutant JMML accompanied by coordinated activation of oxidative phosphorylation (OXPHOS) across primitive hematopoietic compartments. These findings identify mitochondrial OXPHOS as a defining metabolic feature of KRAS-mutant JMML stem/progenitor cells.

To determine whether this metabolic state represents a therapeutic vulnerability, we established KrasG12D-driven JMML mouse transplantation models and serially transplantable KRAS-mutant JMML patient-derived xenograft (PDX) models. Functional transplantation studies established the LSK compartment as the leukemia-propagating population in Kras-driven JMML. Importantly, Kras-mutant LSK cells exhibited marked enrichment of OXPHOS-associated transcriptional programs compared with control LSK cells, indicating that metabolic rewiring occurs within leukemia-propagating stem/progenitor cells. Pharmacologic inhibition of mitochondrial complex I using IACS-010759 significantly prolonged survival, reduced splenomegaly and hepatomegaly, normalized myeloid differentiation and diminished LSK expansion in Kras-driven JMML mice. IACS-010759 also significantly prolonged survival in serially transplantable KRAS-mutant JMML PDX models. These findings establish OXPHOS as a therapeutically actionable metabolic dependency in KRAS-mutant JMML.

To define the molecular basis of this metabolic program, we integrated single-cell transcriptomic and chromatin accessibility datasets from primary JMML samples. Integrative analysis identified IGF2BP3 as the top candidate exhibiting coordinated increases in gene expression and chromatin accessibility within KRAS-mutant HSC/MPP populations. Motif enrichment analysis identified EGR1 as the upstream transcription factor regulating IGF2BP3. ChIP-qPCR confirmed direct EGR1 binding to the IGF2BP3 promoter, and KRAS activation induced coordinated upregulation of EGR1 and IGF2BP3 protein expression. These findings establish IGF2BP3 as the central downstream effector of an EGR1-dependent transcriptional program linking oncogenic KRAS signaling to OXPHOS activation in JMML stem/progenitor cells.

We next investigated the functional requirement for IGF2BP3 in JMML progression. shRNA-mediated depletion of IGF2BP3 impaired cytokine-independent proliferation and significantly reduced mitochondrial respiration in KRASG12D-transformed TF-1 cells. In vivo, CRISPR-mediated Igf2bp3 targeting and genetic heterozygous Igf2bp3 deletion each significantly prolonged survival of Kras-driven JMML recipients and attenuated myeloid expansion. Single-cell RNA sequencing of Kras-mutant LSK cells further demonstrated marked suppression of OXPHOS-associated transcriptional programs following Igf2bp3 reduction. These data establish IGF2BP3 as an essential regulator of leukemia-propagating stem/progenitor cell fitness and mitochondrial metabolism in KRAS-driven JMML.

Mechanistically, integrated RNA sequencing, m6A RNA immunoprecipitation sequencing and RNA immunoprecipitation identified the transcriptional corepressor CBFA2T3 as a direct m6A-modified target of IGF2BP3. IGF2BP3 bound CBFA2T3 transcripts, enhanced their stability, and prevented transcript decay following transcriptional blockade, whereas IGF2BP3 depletion reduced both CBFA2T3 mRNA and protein expression. Functional suppression of CBFA2T3 phenocopied IGF2BP3 loss by impairing cytokine-independent proliferation and mitochondrial respiration in KRAS-transformed cells. Together, our study defines a previously unrecognized KRAS–EGR1–IGF2BP3–CBFA2T3 signaling axis linking oncogenic KRAS signaling to epitranscriptomic regulation of mitochondrial metabolism, identifies OXPHOS as a therapeutic vulnerability, and supports therapeutic targeting in this high-risk pediatric malignancy.

Jingliao Zhang, MD: No relevant conflicts of interest to declare.